Peginterferon alfa-2b
A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa 2b) and Actimmune® (Interferon gamma 1b) for intra peritoneal administration in recurrent ovarian cancer
... (Peginterferon alfa-2b) and Actimmune ® (Interferon gamma-1b) and autologous monocytes with monocytes is a novel approach to maximize the anti-tumor proper- ties of all three ...
9
Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
... The objective of this analysis was to compare treatment costs and outcomes of pegylated interferon-alfa-2a versus pegylated interferon-alfa-2b, both associated with ribavirin, in the therapeutic ...
9
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
... and peginterferon alfa-2b in patients with unresectable mel- ...Interferon alfa treatment has been shown to induce an inflammatory tumor microenvironment, with upregulation of major ...
8
Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China
... This study was designed as a LTFU for the original multicenter, randomized, controlled study (P05170) [20] in which 657 interferon-naïve CHB patients were ran- domized to receive different PEG-IFN alfa-2b ...
11
(INF- ) in combination
... Boceprevir, another NS3/4A serine protease inhibitor, binds reversibly to the NS3 protease active site and has potent anti HCV activity alone and in combination with interferon alfa-2b. SPRINT-1 study ...
5
The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
... feron alfa-2a (IFN-2a) or interferon alfa-2b (IFN-2b) at a dose of 3 million units, thrice a week subcutaneously combined with an oral dose ribavirin: 1,000 mg/day for patients under 75 kg and ...
9
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
... A Phase Ib study of ipilimumab with peginterferon alfa-2b (H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, and Merck Sharp & Dohme Corp, ClinicalTrials.[r] ...
11
s-2003-41630.pdf
... of peginterferon alfa-2b plus ribavirin results in an early hepati- tis C virus (HCV) RNA decay followed by an increase as the drug concentration declines between ...
6
Treatment emergent depression and anxiety between peginterferon alpha 2a versus alpha 2b plus ribavirin for chronic hepatitis C
... are peginterferon alfa-2a (PegIFN-α-2a) and peginterferon alfa-2b (PegIFN-α-2b), which differ in their pharmaco- kinetics and chemical properties; both are cost-effective and ...
8
A prospective Study on Adverse Drug Reactions from Pegylated Interferon Alfa-2a and Alfa-2b in Combination with Ribavirin in Hepatitis B and C
... (peginterferon alfa-2a and peginterferon alfa-2b) have significantly improved pharmacokinetics, resulting in improved antiviral efficacy, which also has the potential to alter the side ...
6
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
... agalsidase alfa, several reports using the database of Fabry Outcome Survey (FOS) [21], an international, multicenter, collaborative study sponsored by Shire have been ...agalsidase alfa for 5 years, and ...
9
Effect of Blending Ratio of Fibers on the Properties of Nonwoven Fabrics Based of Alfa Fibers
... of Alfa fibers in nonwoven. Extracted Alfa fibers present satisfying mechanical properties that al- low them to be used to produce nonwoven textiles ...Therefore, Alfa fibers are, mainly, blended ...
10
An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
... Taliglucerase alfa has dose-dependent beneficial effects on the major manifestations of type I Gaucher ...Taliglucerase alfa would be a very welcome addition to the treatment arsenal for Gaucher disease, as ...
6
Recombinant follitropin alfa/lutropin alfa in fertility treatment
... Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who [r] ...
13
Shrinkwrap and Clickwrap Agreements: 2B or Not 2B?
... present the final version to state legislatures by the new millennium. 3 Although UCITA renders shrinkwrap and clickwrap agreements generally enforceable, it also explicitly[r] ...
27
The safety profile of drotrecogin alfa (activated)
... Drotrecogin alfa (activated; DrotAA) is the first and thus far only compound proven to improve survival in patients with severe sepsis. The mechanisms that underlie the improved survival are not entirely clear. A ...
8
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
... One hundred and ninety-one (31%) of the 608 patients who received allotted intervention in the pegIFNa-2b group discontinued treatment because of toxicities. The most common toxicities that prompted ...
10
Successful Antiangiogenic Therapy of Giant Cell Angioblastoma With Interferon Alfa 2b: Report of 2 Cases
... sc daily. After 6 days of therapy, the patient’s SGOT rose to 274 (normal range for infant ⬍ 1 year: 10 – 65) and IFN␣2b was stopped. Over the next few weeks, the SGOT decreased to 73 and the medication was ...
7
Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats
... follitropin alfa RFF and five 75 IU mono-dose vials of lutropin alfa were reconsti- tuted with their accompanying diluent (1 ml Sterile Water for Injection [SWFI]) for each ...follitropin alfa RFF ...
6
Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients
... who presented stable hemoglobin levels of 10–11.5 g/dL with standard liquid EPO alfa product (EPREX, Cilag AG, Schaffhausen, Switzerland) treatment for at least 12 weeks. All patients had adequate dialysis by a ...
9